Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Pragmatiston Dec 06, 2020 7:15pm
187 Views
Post# 32046985

RE:RE:RE:News

RE:RE:RE:News
Doc, I think that the hiring of the US-based, senior business development officer, the rainmaker/dealmaker will be a significant event.  It will indicate that big partnering discussions are coming.
 
In the final prospectus and subsequent events, the company stated that it would be hiring this individual to manage the big deals.  It earmarked $750K for his hiring and first year salary, a significant amount, given that this is more than the salaries of Legault/Wallace combined.
 
I have looked into large bioteck deals and have come to the conclusion that it is rocket science.  It requires specialized skills, and the right negotiator can add significant value. So it would be appropriate to bring someone onboard when the time is right.
 
I think the senior BDO is separate from the recent Board appointments.  The Board provides oversight, governance and  advice, and maybe can open some doors.  But it is not an negotiator. Hence the need for the new BDO. At least that is how I see it.
 
Or has the company's approach changed, and they are prepared to go forward with the current team?
<< Previous
Bullboard Posts
Next >>